Rexahn Pharmaceuticals, Inc. (REXN) - Posters https://www.https://asset.cdnnest.com/20200508101811im_/https://rexahn.com/news-media/posters The latest news released by Rexahn Pharmaceuticals, Inc. en-us Equisolve https://d1io3yog0oux5.cloudfront.net/_2d6b27f41d508df3c55bdf0427af22d3/rexahn/logo.png Rexahn Pharmaceuticals, Inc. https://www.rexahn.com 88 31 RX-5902 exhibits direct and immunomodulatory anti-tumor activities in melanoma PDX models https://www.rexahn.com/news-media/posters/detal/3256/rx-5902-exhibits-direct-and-immunomodulatory-anti-tumor-activities-in-melanoma-pdx-models Tue, 02 Apr 2019 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3256/rx-5902-exhibits-direct-and-immunomodulatory-anti-tumor-activities-in-melanoma-pdx-models Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117) https://www.rexahn.com/news-media/posters/detal/3254/unusual-mechanism-of-resistance-to-the-novel-cytidine-analog-fluorocyclopentenylcytosine-rx-3117 Mon, 01 Apr 2019 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3254/unusual-mechanism-of-resistance-to-the-novel-cytidine-analog-fluorocyclopentenylcytosine-rx-3117 The anticancer effects of RX-5902 result from inhibition of phosphorylated p68-mediated β-catenin nuclear translocation https://www.rexahn.com/news-media/posters/detal/3253/the-anticancer-effects-of-rx-5902-result-from-inhibition-of-phosphorylated-p68-mediated--catenin-nuclear-translocation Mon, 01 Apr 2019 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3253/the-anticancer-effects-of-rx-5902-result-from-inhibition-of-phosphorylated-p68-mediated--catenin-nuclear-translocation Phenotyping pancreatic cancer CTCs as biomarkers for RX-3117 clinical trial https://www.rexahn.com/news-media/posters/detal/3252/phenotyping-pancreatic-cancer-ctcs-as-biomarkers-for-rx-3117-clinical-trial Sun, 31 Mar 2019 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3252/phenotyping-pancreatic-cancer-ctcs-as-biomarkers-for-rx-3117-clinical-trial Results of a Phase 2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma (mRCC) https://www.rexahn.com/news-media/posters/detal/3236/results-of-a-phase-2-study-to-evaluate-the-safety-and-efficacy-of-rx-0201-in-combination-with-everolimus-in-subjects-with-metastatic-renal-cell-carcinoma-mrcc Sat, 16 Feb 2019 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3236/results-of-a-phase-2-study-to-evaluate-the-safety-and-efficacy-of-rx-0201-in-combination-with-everolimus-in-subjects-with-metastatic-renal-cell-carcinoma-mrcc Activity of RX-3117, an Oral Antimetabolite Nucleoside, in Subjects with Advanced Urothelial Cancer: Preliminary Results from a Phase IIa Study https://www.rexahn.com/news-media/posters/detal/3235/activity-of-rx-3117-an-oral-antimetabolite-nucleoside-in-subjects-with-advanced-urothelial-cancer-preliminary-results-from-a-phase-iia-study Fri, 15 Feb 2019 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3235/activity-of-rx-3117-an-oral-antimetabolite-nucleoside-in-subjects-with-advanced-urothelial-cancer-preliminary-results-from-a-phase-iia-study Phase 1/2 Study Of Rx-3117, An Oral Antimetabolite Nucleoside, In Combination With Nab-Paclitaxel (Nab-Pac) As First Line Treatment of Metastatic Pancreatic Cancer (Met-Pc):Preliminary Results https://www.rexahn.com/news-media/posters/detal/3210/phase-12-study-of-rx-3117-an-oral-antimetabolite-nucleoside-in-combination-with-nab-paclitaxel-nab-pac-as-first-line-treatment-of-metastatic-pancreatic-cancer-met-pc-preliminary-results Fri, 18 Jan 2019 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3210/phase-12-study-of-rx-3117-an-oral-antimetabolite-nucleoside-in-combination-with-nab-paclitaxel-nab-pac-as-first-line-treatment-of-metastatic-pancreatic-cancer-met-pc-preliminary-results RX-3117, A Novel, Oral Nucleoside Analog, in Combination with Nab-paclitaxel (NAB-PAC) in First-line Metastatic Pancreatic Cancer (MET-PC): Safety, Tolerability, and Preliminary Responses https://www.rexahn.com/news-media/posters/detal/3028/rx-3117-a-novel-oral-nucleoside-analog-in-combination-with-nab-paclitaxel-nab-pac-in-first-line-metastatic-pancreatic-cancer-met-pc-safety-tolerability-and-preliminary-responses Tue, 02 Oct 2018 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3028/rx-3117-a-novel-oral-nucleoside-analog-in-combination-with-nab-paclitaxel-nab-pac-in-first-line-metastatic-pancreatic-cancer-met-pc-safety-tolerability-and-preliminary-responses Presented at the 5th NCI Pancreatic Cancer Symposium held at the National Institutes of Health in Bethesda, Maryland – October 2-3, 2018]]> Preliminary Results From an Ongoing Phase 2a Study of RX-3117, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC) https://www.rexahn.com/news-media/posters/detal/3030/preliminary-results-from-an-ongoing-phase-2a-study-of-rx-3117-an-oral-nucleoside-analogue-to-treat-advanced-urothelial-cancer-auc Fri, 01 Jun 2018 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3030/preliminary-results-from-an-ongoing-phase-2a-study-of-rx-3117-an-oral-nucleoside-analogue-to-treat-advanced-urothelial-cancer-auc Presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting – Chicago, IL, June 1–5, 2018]]> Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68), Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC) https://www.rexahn.com/news-media/posters/detal/3029/preliminary-report-of-a-phase-1b2a-trial-an-oral-inhibitor-of-phosphorylated-p68-p-p68-which-mediates--catenin-nuclear-translocation-in-advanced-triple-negative-breast-cancer-tnbc Fri, 01 Jun 2018 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3029/preliminary-report-of-a-phase-1b2a-trial-an-oral-inhibitor-of-phosphorylated-p68-p-p68-which-mediates--catenin-nuclear-translocation-in-advanced-triple-negative-breast-cancer-tnbc Presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting – Chicago, IL, June 1–5, 2018]]> RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1 https://www.rexahn.com/news-media/posters/detal/3031/rx-3117-promotes-epigenetic-effects-in-cancer-cells-through-enhanced-degradation-of-dnmt1 Sat, 14 Apr 2018 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3031/rx-3117-promotes-epigenetic-effects-in-cancer-cells-through-enhanced-degradation-of-dnmt1 Presented at the American Association for Cancer Research (AACR) 109th Annual Meeting, Chicago, Illinois, April 14-18, 2018]]> RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advance Urothelial Cancer (aUC) https://www.rexahn.com/news-media/posters/detal/3032/rx-3117-an-oral-hypomethylating-agent-to-treat-advanced-solid-tumors-st-interim-results-from-an-ongoing-phase-2a-study-in-advance-urothelial-cancer-auc Thu, 08 Feb 2018 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3032/rx-3117-an-oral-hypomethylating-agent-to-treat-advanced-solid-tumors-st-interim-results-from-an-ongoing-phase-2a-study-in-advance-urothelial-cancer-auc Presented at the ASCO Genitourinary Cancers Symposium, San Francisco, CA, Feb 8 –10, 2018]]> RX3117: Activity of an Oral Antimetabolite Nucleoside in Subjects with Pancreatic Cancer – Preliminary Results of Stage II of the Phase Ia/IIb Study https://www.rexahn.com/news-media/posters/detal/3033/rx3117-activity-of-an-oral-antimetabolite-nucleoside-in-subjects-with-pancreatic-cancer-preliminary-results-of-stage-ii-of-the-phase-iaiib-study Thu, 18 Jan 2018 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3033/rx3117-activity-of-an-oral-antimetabolite-nucleoside-in-subjects-with-pancreatic-cancer-preliminary-results-of-stage-ii-of-the-phase-iaiib-study Presented at the ASCO Gastrointestinal Cancers Symposium, Jan 18 – 20, 2018]]> Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer https://www.rexahn.com/news-media/posters/detal/3034/preclinical-studies-of-rx-5902-a-beta-catenin-modulator-in-triple-negative-breast-cancer Tue, 05 Dec 2017 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3034/preclinical-studies-of-rx-5902-a-beta-catenin-modulator-in-triple-negative-breast-cancer Presented at 40th Annual San Antonio Breast Cancer Symposium – San Antonio, Texas, December 5-9, 2017]]> A Novel Small Molecule Nucleoside Analog, RX-3117, Shows Potent Therapeutic Activity in Combination with Nab-paclitaxel and Checkpoint Inhibitors in Xenograft Models https://www.rexahn.com/news-media/posters/detal/3037/a-novel-small-molecule-nucleoside-analog-rx-3117-shows-potent-therapeutic-activity-in-combination-with-nab-paclitaxel-and-checkpoint-inhibitors-in-xenograft-models Mon, 11 Sep 2017 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3037/a-novel-small-molecule-nucleoside-analog-rx-3117-shows-potent-therapeutic-activity-in-combination-with-nab-paclitaxel-and-checkpoint-inhibitors-in-xenograft-models 2017 European Society for Medical Oncology (ESMO) Congress – Madrid, Spain, September 8-12, 2017]]> Phase 1 study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents β-catenin Translocation in Advanced Solid Tumors https://www.rexahn.com/news-media/posters/detal/3036/phase-1-study-of-rx-5902-a-novel-orally-bioavailable-inhibitor-of-phosphorylated-p68-which-prevents--catenin-translocation-in-advanced-solid-tumors Mon, 11 Sep 2017 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3036/phase-1-study-of-rx-5902-a-novel-orally-bioavailable-inhibitor-of-phosphorylated-p68-which-prevents--catenin-translocation-in-advanced-solid-tumors 2017 European Society for Medical Oncology (ESMO) Congress – Madrid, Spain, September 8-12, 2017]]> RX-3117, An Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advanced Urothelial Cancer https://www.rexahn.com/news-media/posters/detal/3035/rx-3117-an-oral-hypomethylating-agent-to-treat-advanced-solid-tumors-st-interim-results-from-an-ongoing-phase-2a-study-in-advanced-urothelial-cancer Sun, 10 Sep 2017 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3035/rx-3117-an-oral-hypomethylating-agent-to-treat-advanced-solid-tumors-st-interim-results-from-an-ongoing-phase-2a-study-in-advanced-urothelial-cancer 2017 European Society for Medical Oncology (ESMO) Congress – Madrid, Spain, September 8-12, 2017]]> Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ib/IIa study. https://www.rexahn.com/news-media/posters/detal/3038/activity-of-rx-3117-an-oral-antimetabolite-nucleoside-in-subjects-with-metastatic-bladder-cancer-resistant-to-gemcitabine-preliminary-results-of-a-phase-ibiia-study Fri, 02 Jun 2017 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3038/activity-of-rx-3117-an-oral-antimetabolite-nucleoside-in-subjects-with-metastatic-bladder-cancer-resistant-to-gemcitabine-preliminary-results-of-a-phase-ibiia-study American Society of Clinical Oncology (ASCO) 2017 Annual Meeting – Chicago, IL, Jun 2–6, 2017]]> RX3117, An Oral Antimetabolite Nucleoside Shows Activity in Subjects with Pancreatic Cancer. Preliminary Results of Stage 1 of the Phase 1a/2b Study https://www.rexahn.com/news-media/posters/detal/3039/rx3117-an-oral-antimetabolite-nucleoside-shows-activity-in-subjects-with-pancreatic-cancer-preliminary-results-of-stage-1-of-the-phase-1a2b-study Thu, 19 Jan 2017 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3039/rx3117-an-oral-antimetabolite-nucleoside-shows-activity-in-subjects-with-pancreatic-cancer-preliminary-results-of-stage-1-of-the-phase-1a2b-study Presented at the ASCO Genitourinary Cancers Symposium, San Francisco, CA, Jan 19 –21, 2017]]> Phase 1/2a Study of RX-5902 in Advanced Solid Tumors (ST): an Orally Bioavailable Inhibitor of Phosphorylated p68 and Modulator of β-Catenin Nuclear Translocation https://www.rexahn.com/news-media/posters/detal/3041/phase-12a-study-of-rx-5902-in-advanced-solid-tumors-st-an-orally-bioavailable-inhibitor-of-phosphorylated-p68-and-modulator-of--catenin-nuclear-translocation Fri, 07 Oct 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3041/phase-12a-study-of-rx-5902-in-advanced-solid-tumors-st-an-orally-bioavailable-inhibitor-of-phosphorylated-p68-and-modulator-of--catenin-nuclear-translocation Presented at the ESMO 2016 Congress From disease treatment to patient care, Oct 7 – 11, 2016]]> RX-3117, An Oral Antimetabolite to Treat Advanced Solid Tumors (ST): Phase 1 and Ongoing Phase 2a Results https://www.rexahn.com/news-media/posters/detal/3040/rx-3117-an-oral-antimetabolite-to-treat-advanced-solid-tumors-st-phase-1-and-ongoing-phase-2a-results Fri, 07 Oct 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3040/rx-3117-an-oral-antimetabolite-to-treat-advanced-solid-tumors-st-phase-1-and-ongoing-phase-2a-results Presented at the ESMO 2016 Congress From disease treatment to patient care, Oct 7 – 11, 2016]]> Results of a Phase 1 Study of RX-5902, an Orally Bioavailable Inhibitor of Phosphorylated p68, Targeting Solid Tumors https://www.rexahn.com/news-media/posters/detal/3239/results-of-a-phase-1-study-of-rx-5902-an-orally-bioavailable-inhibitor-of-phosphorylated-p68-targeting-solid-tumors Mon, 06 Jun 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3239/results-of-a-phase-1-study-of-rx-5902-an-orally-bioavailable-inhibitor-of-phosphorylated-p68-targeting-solid-tumors Results of a Phase 1 Study of Single Agent RX-3117: An Oral Antimetabolite Nucleoside to Treat Solid Tumors https://www.rexahn.com/news-media/posters/detal/3238/results-of-a-phase-1-study-of-single-agent-rx-3117-an-oral-antimetabolite-nucleoside-to-treat-solid-tumors Mon, 06 Jun 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3238/results-of-a-phase-1-study-of-single-agent-rx-3117-an-oral-antimetabolite-nucleoside-to-treat-solid-tumors Results from a Phase 1b/2 Study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma https://www.rexahn.com/news-media/posters/detal/3237/results-from-a-phase-1b2-study-of-rx-0201-a-novel-akt-1-antisense-combined-with-everolimus-to-treat-metastatic-clear-cell-renal-carcinoma Mon, 06 Jun 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3237/results-from-a-phase-1b2-study-of-rx-0201-a-novel-akt-1-antisense-combined-with-everolimus-to-treat-metastatic-clear-cell-renal-carcinoma Inhibition of DNA Methyltransferase by RX-3117 Leads to Upregulation of Hypomethylated Targets https://www.rexahn.com/news-media/posters/detal/3044/inhibition-of-dna-methyltransferase-by-rx-3117-leads-to-upregulation-of-hypomethylated-targets Sat, 16 Apr 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3044/inhibition-of-dna-methyltransferase-by-rx-3117-leads-to-upregulation-of-hypomethylated-targets Presented at American Association for Cancer Research (AACR) 107th Annual Meeting, Apr 16 – 20, 2016]]> Folate Receptor-Targeted Lipid Coated Albumin Nanoparticles (F-LCAN) for Therapeutic Delivery of RX-0201 (Archexin®), an Antisense Oligonucleotide Against AKT-1 https://www.rexahn.com/news-media/posters/detal/3043/folate-receptor-targeted-lipid-coated-albumin-nanoparticles-f-lcan-for-therapeutic-delivery-of-rx-0201-archexin-an-antisense-oligonucleotide-against-akt-1 Sat, 16 Apr 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3043/folate-receptor-targeted-lipid-coated-albumin-nanoparticles-f-lcan-for-therapeutic-delivery-of-rx-0201-archexin-an-antisense-oligonucleotide-against-akt-1 Presented at American Association for Cancer Research (AACR) 107th Annual Meeting, Apr 16 – 20, 2016]]> Phase Ib/II Study of RX-0201, a Novel AKT-1 Antisense Combined with Everolimus to Treat Metastatic Renal Cell Carcinoma – Phase Ib Results https://www.rexahn.com/news-media/posters/detal/3042/phase-ibii-study-of-rx-0201-a-novel-akt-1-antisense-combined-with-everolimus-to-treat-metastatic-renal-cell-carcinoma-phase-ib-results Sat, 16 Apr 2016 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3042/phase-ibii-study-of-rx-0201-a-novel-akt-1-antisense-combined-with-everolimus-to-treat-metastatic-renal-cell-carcinoma-phase-ib-results Presented at American Association for Cancer Research (AACR) 107th Annual Meeting, Apr 16 – 20, 2016]]> The Anticancer Effects of Supinoxin (RX-5902) in Pancreatic Cancer https://www.rexahn.com/news-media/posters/detal/3046/the-anticancer-effects-of-supinoxin-rx-5902-in-pancreatic-cancer Thu, 21 Jan 2016 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3046/the-anticancer-effects-of-supinoxin-rx-5902-in-pancreatic-cancer Presented at the ASCO Gastrointestinal Cancers Symposium, Jan 21 – 23, 2016]]> RX-5902 a Phosphorylated p68 Targeting Agent to Treat Subjects with Advanced Solid Tumors https://www.rexahn.com/news-media/posters/detal/3045/rx-5902-a-phosphorylated-p68-targeting-agent-to-treat-subjects-with-advanced-solid-tumors Thu, 21 Jan 2016 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3045/rx-5902-a-phosphorylated-p68-targeting-agent-to-treat-subjects-with-advanced-solid-tumors Presented at the ASCO Gastrointestinal Cancers Symposium, Jan 21 – 23, 2016]]> The Anticancer Effects of Supinoxin(RX-5902) in Renal Cell Cancer https://www.rexahn.com/news-media/posters/detal/3048/the-anticancer-effects-of-supinoxinrx-5902-in-renal-cell-cancer Thu, 07 Jan 2016 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3048/the-anticancer-effects-of-supinoxinrx-5902-in-renal-cell-cancer Presented at the ASCO Genitourinary Cancers Symposium, San Francisco, CA, Jan 7 – 9, 2016]]> Archexin, A Novel AKT-1 Specific Inhibitor for the Treatment of Metastatic Renal Cancer – Preliminary Stage 1 Data https://www.rexahn.com/news-media/posters/detal/3047/archexin-a-novel-akt-1-specific-inhibitor-for-the-treatment-of-metastatic-renal-cancer-preliminary-stage-1-data Thu, 07 Jan 2016 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3047/archexin-a-novel-akt-1-specific-inhibitor-for-the-treatment-of-metastatic-renal-cancer-preliminary-stage-1-data Presented at the ASCO Genitourinary Cancers Symposium, San Francisco, CA, Jan 7 – 9, 2016]]> New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer https://www.rexahn.com/news-media/posters/detal/3049/new-data-demonstrate-supinoxin-dose-dependently-inhibits-tumor-cell-growth-in-a-preclinical-model-of-triple-negative-breast-cancer Tue, 08 Dec 2015 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3049/new-data-demonstrate-supinoxin-dose-dependently-inhibits-tumor-cell-growth-in-a-preclinical-model-of-triple-negative-breast-cancer Presented at The 38th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Dec 8 – 10, 2015]]> RX-0201, An Anti-Sense Targeting AKT-1 to Treat Metastatic Renal Cancer – Preliminary Stage 1 Data https://www.rexahn.com/news-media/posters/detal/3050/rx-0201-an-anti-sense-targeting-akt-1-to-treat-metastatic-renal-cancer-preliminary-stage-1-data Fri, 06 Nov 2015 00:00:00 -0500 https://www.rexahn.com/news-media/posters/detal/3050/rx-0201-an-anti-sense-targeting-akt-1-to-treat-metastatic-renal-cancer-preliminary-stage-1-data Presented at the 14th Annual Kidney Cancer Symposium, Miami, FL, Nov 6 – 7, 2015)]]> Preliminary phase 1 data of single agent RX-3117, an oral antimetabolite nucleoside https://www.rexahn.com/news-media/posters/detal/3052/preliminary-phase-1-data-of-single-agent-rx-3117-an-oral-antimetabolite-nucleoside Fri, 25 Sep 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3052/preliminary-phase-1-data-of-single-agent-rx-3117-an-oral-antimetabolite-nucleoside Presented at the 2015 The European Cancer Congress (ECC 2015) Annual Meeting, Vienna, Austria, Sep 25 – 29, 2015]]> Single Agent Supinoxin Targeting Phosphorylated p-68, Preliminary Phase I Data https://www.rexahn.com/news-media/posters/detal/3051/single-agent-supinoxin-targeting-phosphorylated-p-68-preliminary-phase-i-data Fri, 25 Sep 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3051/single-agent-supinoxin-targeting-phosphorylated-p-68-preliminary-phase-i-data Presented at the 2015 The European Cancer Congress (ECC 2015) Annual Meeting, Vienna, Austria, Sep 25 – 29, 2015]]> A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors https://www.rexahn.com/news-media/posters/detal/3056/a-phase-1-exploratory-study-of-rx-3117-to-determine-oral-bioavailability-in-cancer-subjects-with-solid-tumors Fri, 29 May 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3056/a-phase-1-exploratory-study-of-rx-3117-to-determine-oral-bioavailability-in-cancer-subjects-with-solid-tumors Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015]]> A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma https://www.rexahn.com/news-media/posters/detal/3055/a-multicenter-open-label-proof-of-concept-phase-1b2-study-to-evaluate-the-safety-and-efficacy-of-rx-0201-in-combination-with-everolimus-to-treat-subjects-with-advanced-renal-cell-carcinoma Fri, 29 May 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3055/a-multicenter-open-label-proof-of-concept-phase-1b2-study-to-evaluate-the-safety-and-efficacy-of-rx-0201-in-combination-with-everolimus-to-treat-subjects-with-advanced-renal-cell-carcinoma Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015]]> A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors https://www.rexahn.com/news-media/posters/detal/3054/a-phase-i-study-of-rx-3117-an-oral-agent-activated-by-uridine-cytidine-kinase-2-to-treat-subjects-with-advanced-solid-tumors Fri, 29 May 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3054/a-phase-i-study-of-rx-3117-an-oral-agent-activated-by-uridine-cytidine-kinase-2-to-treat-subjects-with-advanced-solid-tumors Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015]]> A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors https://www.rexahn.com/news-media/posters/detal/3053/a-phase-1-study-of-rx-5902-an-oral-agent-targeting-phosphorylated-p68-to-treat-subjects-with-advanced-solid-tumors Fri, 29 May 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3053/a-phase-1-study-of-rx-5902-an-oral-agent-targeting-phosphorylated-p68-to-treat-subjects-with-advanced-solid-tumors Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015]]> Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902) https://www.rexahn.com/news-media/posters/detal/3058/targeting-localization-and-function-of-the-rna-helicase-ddx5p68-with-1-35-imethoxyphenyl-4-6-fluoro-2-methoxyquinoxalin-3-yl-aminocarbonyl-piperazine-rx-5902 Sat, 18 Apr 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3058/targeting-localization-and-function-of-the-rna-helicase-ddx5p68-with-1-35-imethoxyphenyl-4-6-fluoro-2-methoxyquinoxalin-3-yl-aminocarbonyl-piperazine-rx-5902 Presented at the American Association for Cancer Research (AACR) 106th Annual Meeting, Philadelphia, Pennsylvania, April 18-22, 2015]]> Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker https://www.rexahn.com/news-media/posters/detal/3057/fluorocyclopentenylcytosine-rx-3117-is-activated-by-uridine-cytidine-kinase-2-a-potential-biomarker Sat, 18 Apr 2015 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3057/fluorocyclopentenylcytosine-rx-3117-is-activated-by-uridine-cytidine-kinase-2-a-potential-biomarker Presented at the American Association for Cancer Research (AACR) 106th Annual Meeting, Philadelphia, Pennsylvania, April 18-22, 2015]]> Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy https://www.rexahn.com/news-media/posters/detal/3060/synthesis-of-targeted-docetaxel-polymer-conjugate-and-its-anti-tumor-efficacy Sat, 05 Apr 2014 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3060/synthesis-of-targeted-docetaxel-polymer-conjugate-and-its-anti-tumor-efficacy Presented at the American Association for Cancer Research (AACR) 105th Annual Meeting, San Diego, California, April 5-9, 2014]]> A novel small molecule cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to treatment with gemcitabine https://www.rexahn.com/news-media/posters/detal/3059/a-novel-small-molecule-cytidine-analog-rx-3117-shows-potent-efficacy-in-xenograft-models-even-in-tumors-that-are-resistant-to-treatment-with-gemcitabine Sat, 05 Apr 2014 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3059/a-novel-small-molecule-cytidine-analog-rx-3117-shows-potent-efficacy-in-xenograft-models-even-in-tumors-that-are-resistant-to-treatment-with-gemcitabine Presented at the American Association for Cancer Research (AACR) 105th Annual Meeting, San Diego, California, April 5-9, 2014]]> Mechanistic study of a new 4-(3, 5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902) https://www.rexahn.com/news-media/posters/detal/3061/mechanistic-study-of-a-new-4-3-5-dimethoxyphenyl-n-7-fluoro-3-methoxyquinoxalin-2-ylpiperazine-1-carboxamide-compound-rx-5902 Sat, 06 Apr 2013 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3061/mechanistic-study-of-a-new-4-3-5-dimethoxyphenyl-n-7-fluoro-3-methoxyquinoxalin-2-ylpiperazine-1-carboxamide-compound-rx-5902 Presented at the American Association for Cancer Research (AACR) 104th Annual Meeting, Washington, D.C., April 6-10, 2013]]> Anti-tumor activity of a new quinoxalinyl-piperazine compound (RX-5902) https://www.rexahn.com/news-media/posters/detal/3062/anti-tumor-activity-of-a-new-quinoxalinyl-piperazine-compound-rx-5902 Sat, 02 Apr 2011 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3062/anti-tumor-activity-of-a-new-quinoxalinyl-piperazine-compound-rx-5902 Present data on novel Anti-Cancer Small Molecule RX-5902 at AACR 102nd Annual Meeting, Orlando, FL, April 2-6, 2011]]> Characterization of a novel small molecule with potent anticancer activity (RX-8243) https://www.rexahn.com/news-media/posters/detal/3063/characterization-of-a-novel-small-molecule-with-potent-anticancer-activity-rx-8243 Sat, 17 Apr 2010 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3063/characterization-of-a-novel-small-molecule-with-potent-anticancer-activity-rx-8243 Presented at the American Association for Cancer Research (AACR) 101st Annual Meeting, Washington, D.C., April 17-21, 2010]]> A Phase I Trial of RX-0201 (Archexin; akt-1 Antisense) in Patients with An Advanced Cancer https://www.rexahn.com/news-media/posters/detal/3064/a-phase-i-trial-of-rx-0201-archexin-akt-1-antisense-in-patients-with-an-advanced-cancer Fri, 01 Jun 2007 00:00:00 -0400 https://www.rexahn.com/news-media/posters/detal/3064/a-phase-i-trial-of-rx-0201-archexin-akt-1-antisense-in-patients-with-an-advanced-cancer Presented at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2007]]>